These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37869647)

  • 21. Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
    Auffret V; Leurent G; Boulmier D; Bedossa M; Zabalawi A; Hacot JP; Coudert I; Filippi E; Castellant P; Rialan A; Rouault G; Druelles P; Boulanger B; Treuil J; Avez B; Le Guellec M; Gilard M; Le Breton H
    Arch Cardiovasc Dis; 2016 Dec; 109(12):696-707. PubMed ID: 27818120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.
    Valgimigli M; Frigoli E; Leonardi S; Rothenbühler M; Gagnor A; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andò G; Repetto A; Limbruno U; Garbo R; Sganzerla P; Russo F; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Presbitero P; Santarelli A; Sardella G; Varbella F; Tresoldi S; de Cesare N; Rigattieri S; Zingarelli A; Tosi P; van 't Hof A; Boccuzzi G; Omerovic E; Sabaté M; Heg D; Jüni P; Vranckx P;
    N Engl J Med; 2015 Sep; 373(11):997-1009. PubMed ID: 26324049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcomes of Bivalirudin Versus Heparin in Elderly Patients Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Meng S; Xu J; Guo L; Huang R
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):101-111. PubMed ID: 32100149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
    Kumar D; Dangas G; Mehran R; Kirtane A; Bertrand M; Ebrahimi R; Guagliumi G; Brar S; Fahy M; Heller E; Moses J; Stone G
    Am J Cardiol; 2010 Oct; 106(7):941-5. PubMed ID: 20854954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
    Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
    Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of long-term benefits of bivalirudin versus unfractionated heparin in routine clinical practice after percutaneous coronary intervention.
    Vidi VD; Matheny ME; Agarwal V; Arora N; Donnelly S; Bangalore S; Resnic FS
    Am J Cardiol; 2010 Nov; 106(9):1234-40. PubMed ID: 21029818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
    Jovin IS; Shah RM; Patel DB; Rao SV; Baklanov DV; Moussa I; Kennedy KF; Secemsky EA; Yeh RW; Kontos MC; Vetrovec GW
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1102-1111. PubMed ID: 28527778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study.
    Mallidi JR; Robinson P; Visintainer PF; Lotfi AS; Mulvey S; Giugliano GR
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):898-904. PubMed ID: 28417608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.
    Bikdeli B; Erlinge D; Valgimigli M; Kastrati A; Han Y; Steg PG; Stables RH; Mehran R; James SK; Frigoli E; Goldstein P; Li Y; Shahzad A; Schüpke S; Mehdipoor G; Chen S; Redfors B; Crowley A; Zhou Z; Stone GW
    Circulation; 2023 Oct; 148(16):1207-1219. PubMed ID: 37746717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial.
    Zeymer U; van 't Hof A; Adgey J; Nibbe L; Clemmensen P; Cavallini C; ten Berg J; Coste P; Huber K; Deliargyris EN; Day J; Bernstein D; Goldstein P; Hamm C; Steg PG
    Eur Heart J; 2014 Sep; 35(36):2460-7. PubMed ID: 24849104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.
    Chang CC; Chichareon P; Modolo R; Takahashi K; Kogame N; Tomaniak M; Gao C; Royaards KJ; Cequier A; Oldroyd K; Steg PG; Hamm C; Jüni P; Valgimigli M; Windecker S; Onuma Y; Stables RH; Jan van Geuns R; Serruys PW
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):22-30. PubMed ID: 31841136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
    N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of bivalirudin in elderly patients with coronary artery disease undergoing percutaneous coronary intervention: A real-world study.
    Li J; Liu X; Ma S; Na K; Qi Z; Xu Y; Qiu M; Han Y; Li Y
    Catheter Cardiovasc Interv; 2022 May; 99 Suppl 1():1448-1455. PubMed ID: 35077603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
    Carswell CI; Plosker GL
    Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
    Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.